Abstract
Objective
Calcium channel blocker (CCB) toxicity, in particular that induced by verapamil and diltiazem, presents clinical challenges with no true antidote. Levosimendan, a calcium sensitizer, improves cardiac contractility in patients with heart failure. We tested the hypothesis that calcium channel sensitization will prolong survival in a rat model of severe verapamil poisoning.
Methods
This was a blinded, randomized, controlled animal study. Wistar rats (mean weight, 371 ± 50 g) were used. Verapamil (2.5 mg/ml) was infused at a rate of 37.5 mg/kg per hour. Bolus doses of levosimendan (5 μg/mL) were given at 0 min (12 μg/kg) and 5 min (18 μg/kg); saline control was of equal volume. The rats were intubated and maintained under general anesthesia with isoflurane. Electrocardiographic activity and core temperature were monitored during the poisoning and treatment phases. Each rat underwent femoral vein cannulation and was then randomized, in blinded fashion, to receive either levosimendan or an equal volume of saline at 0 and 5 minutes. Death, defined as 1 minute of asystole, was used as the primary endpoint.
Results
Rats treated with levosimendan died before the control group (7.37 ± 0.7 min [n = 7] vs. 16.4 ± 4.2 [n = 7] [p=.053]). All animals experienced bradycardia prior to asystole.
Discussion
Although levosimendan has the ability to sensitize and enhance binding of troponin C to Ca2+, this study did not show an improvement in survival time in the setting of verapamil toxicity. This may be attributed to levosimendan’s inhibition of phosphodiesterase, which possibly exacerbated the CCB-induced hypotension.
Conclusion
In this rat model, levosimendan as a solitary antidotal treatment for verapamil toxicity was not beneficial.
Keywords: verapamil, toxicity, levosimendan
Full Text
The Full Text of this article is available as a PDF (193.9 KB).
Footnotes
This study was funded by the Maryland Emergency Medicine Grant Network.
References
- 1.Veltri JC, Litovitz TL. 1983 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. 1984;2(5):420–443. doi: 10.1016/0735-6757(84)90046-9. [DOI] [PubMed] [Google Scholar]
- 2.Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual Report of the American Association of Poison Control Centers’ national poisoning and exposure database. Clin Toxicol (Phila) 2006;44(6-7):803–932. doi: 10.1080/15563650600907165. [DOI] [PubMed] [Google Scholar]
- 3.De Luca L, Colucci WS, Nieminen MS, et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart J. 2006;27(16):1908–1920. doi: 10.1093/eurheartj/ehi875. [DOI] [PubMed] [Google Scholar]
- 4.Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: a molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem. 1994;269(46):28584–28590. [PubMed] [Google Scholar]
- 5.Tebbutt S, Harvey M, Nicholson T, et al. Intralipid prolongs survival in a rat model of verapamil toxicity. Acad Emerg Med. 2006;13(2):134–139. doi: 10.1111/j.1553-2712.2006.tb01661.x. [DOI] [PubMed] [Google Scholar]
- 6.Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107(1):81–86. doi: 10.1161/01.CIR.0000043245.00859.11. [DOI] [PubMed] [Google Scholar]
- 7.Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883–1891. doi: 10.1001/jama.297.17.1883. [DOI] [PubMed] [Google Scholar]
- 8.Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102(18):2222–2227. doi: 10.1161/01.cir.102.18.2222. [DOI] [PubMed] [Google Scholar]
- 9.Ajiro Y, Hagiwara N, Katsube Y, et al. Levosimendan increases L-type Ca(2+) current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur J Pharmacol. 2002;435(1):27–33. doi: 10.1016/S0014-2999(01)01569-2. [DOI] [PubMed] [Google Scholar]
- 10.Erdei N, Papp Z, Pollesello P, et al. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol. 2006;148(5):696–702. doi: 10.1038/sj.bjp.0706781. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Dworschak M, Breukelmann D, Hannon JD. The impact of isoflurane during simulated ischemia/reoxygenation on intracellular calcium, contractile function, and arrhythmia in ventricular myocytes. Anesth Analg. 2004;99(5):1302–1307. doi: 10.1213/01.ANE.0000134803.28029.7E. [DOI] [PubMed] [Google Scholar]
- 12.Hanouz JL, Vivien B, Gueugniaud PY, et al. Comparison of the effects of sevoflurane, isoflurane and halothane on rat myocardium. Br J Anaesth. 1998;80(5):621–627. doi: 10.1093/bja/80.5.621. [DOI] [PubMed] [Google Scholar]